Lymphoblastoid interferon alfa treatment in chronic hepatitis C

Archives of Disease in Childhood

Volumn 74, Issue 2, 1996, Pages 152-156

  Iorio, Raffaele ^a   Pensati, Pasqualina ^a   Porzio, Salvatore ^a   Fariello, Immacolata ^a   Guida, Salvatore ^a   Vegnente, Angela ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chronic hepatitis C; Interferon alfa

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; LYMPHOBLAST INTERFERON;

ARTICLE; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS C; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030020037     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.74.2.152     Document Type: Article

References (28)

1. Colombo M, Kuog G, Choo QL, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; ii: 1006-8.
2. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.
3. Alter MJ, Sampliner RE. Hepatitis C and miles to go before we sleep [Editorial]. N Engl J Med 1989; 321: 1538-40.
4. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel counties chronic non-A, non-B hepatitis study team. N Engl J Med 1992; 327: 1899-905.
5. Tomimatsu M, Ishiguro N, Taniai M, et al. Hepatitis C virus antibody in patients with primary liver cancer. Cancer 1993; 72: 683-8.
6. Iorio R, Guida S, Porzio S, Fariello I, Vegnente A. Chronic non-A, non-B hepatitis: role of hepatitis C virus. Arch Dis Child 1993; 68: 219-22.
7. Bortolotti F, Vajro P, Cadrobbi P, et al. Cryptogenic chronic liver disease and hepatitis C virus infection in children. J Hepatol 1992; 15: 73-6.
8. Lau JYN, Davis GL. Managing chronic hepatitis C virus infection. BMJ 1993; 306: 469-70.
9. Pagliaro L, Craxi A, Cammà C, et al. Interferon-alfa for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820-8.
10. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alfa therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.
11. Okamoto H, Sugiyama Y, Okada S. Typing hepatitis C virus by polimerase chain reaction with type-specific primers: application to clinical surveys and tracing infections sources. J Gen Virol 1992; 73: 673-9.
12. Vergani D, Mieli-Vergani G. Type II autoimmune hepatitis. What is the role of the hepatitis C virus? Gaaroenterology 1993; 104: 1870-3.
13. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-6.
14. Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994; 106: 1291-300.
15. Lisker-Melman M, Di Bisceglie AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon-alfa. Gastroenterology 1992; 102: 2155-60.
16. Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before Interferon therapy. Hepatology 1993; 18: 253-7.
17. De Groote J, Desmet VJ, Gedigk P, et al. A classification of chronic hepatitis. Lancet 1968; ii: 626-62.
18. Knodell RG, Ishak HG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
19. Okamoto H, Okada S, Sugiyama Y, et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Japanese Journal of Experimental Medicine 1990; 60: 215-22.
20. Seef LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 1906-11.
21. Ruiz-Moreno M, Rua MJ, Castillo I, et al. Treatment of children with chronic hepatitis C with recombinant interferon-alfa: a pilot study. Hepatology 1992; 16: 882-5.
22. Kumar U, Monjardino J, Thomas HC. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology 1994; 106: 1072-5.
23. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317-22.
24. Yec HF Jr, Wright TL. Serum ALT: tarnished gold standard for interferon response in hepatitis C virus infection. Hepatology 1994; 19: 1531-3.
25. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995; 21: 291-7.
26. Lau YNJ, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet 1993; 342: 1208-9.
27. Terrault N, Wright T. Interferon and hepatitis C. N Engl J Med 1995; 332: 1509-11.
28. Tsubiota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.